Forward Therapeutics, a Palm Beach Gardens, FL-based biopharmaceutical company developing small molecule therapies for chronic immunological and inflammatory disorders, raised $50M in Series A funding.
The round was led by BVF Partners with participation from other life sciences investors RA Capital Management and OrbiMed. Forward Therapeutics has partnered with Curie.Bio, a new model for venture capital in biotech focused on helping founders launch therapeutics companies.
The company intends to use the funds to advance its portfolio of novel, small molecule immunology medicines towards clinical development.
Led by Toufike Kanouni, chief executive officer, and Ewan Taylor, chief scientific officer, Forward Therapeutics is a biopharmaceutical company dedicated to advancing the treatment of chronic inflammatory disorders via a pipeline of novel, next-generation small molecule immune therapies.
FinSMEs
08/11/2023